Home/Clinical Trials
RecruitingPhase 3CT-2023-112
Subcutaneous trelanemab in early Alzheimer's disease
Alzheimer's disease · Neuroscience
Ages 50 to 85 years950 participantsChicago, IL, Berlin, Germany
RecruitingPhase 2CT-2025-114
CLV-318 in treatment-resistant depression
Depression · Neuroscience
Ages 18 to 80 years230 participantsHouston, TX, Sydney, Australia +1 more
Active, not recruitingPhase 3CT-2024-115
Long-term extension of trelanemab
Alzheimer's disease · Neuroscience
Ages 50 to 85 years1,600 participantsBerlin, Germany, Seoul, South Korea
Active, not recruitingPhase 3CT-2026-113
CLV-310 in early Parkinson's disease
Parkinson's disease · Neuroscience
Ages 50 to 85 years2,280 participantsToronto, Canada, Seoul, South Korea +3 more
Not yet recruitingPhase 2CT-2024-127
CLV-318 relapse-prevention study
Depression · Neuroscience
Ages 18 to 75 years160 participantsSydney, Australia, Chicago, IL
Study listings are fictional. Talk with your doctor before joining any clinical trial.